Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Stock Information for Rafael Holdings Inc. Class B

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rafael Holdings Inc. Class B

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.